RNAI Sirna Therapeutics

SAN FRANCISCO, July 5 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi therapeutics company, announced today that J. Michael French, Sirna's Senior Vice President of Corporate Development, is scheduled to give a company presentation at the C.E. Unterberg, Towbin Emerging Growth Conference on Wednesday, July 12, 2006 at 9:06 a.m. EDT at the Mandarin Oriental Hotel in New York City. For more information on this conference, please log onto http://www.unterberg.com/. About Sirna Therapeutics Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, RSV, Huntington's disease, diabetes and oncology. Sirna Therapeutics completed its Phase 1 clinical trial for Sirna-027 in AMD in 2005 and with its strategic partner, Allergan, Inc., will move Sirna-027 into Phase 2 clinical trials in 2006. Sirna has selected a clinical compound for hepatitis C virus, Sirna-034, which the Company plans to bring into Phase 1 clinical trials by the end of 2006. Sirna has established an exclusive multi-year strategic alliance with GlaxoSmithKline for the development of siRNA compounds for the treatment of respiratory diseases. Sirna has a leading intellectual property portfolio in RNAi covering over 250 mammalian gene and viral targets and over 200 issued or pending patents covering other major aspects of RNAi technology, including the microRNA technology. More information on Sirna Therapeutics is available on the Company's web site at http://www.sirna.com/. Safe Harbor Statement Statements in this press release which are not strictly historical are "forward-looking" statements which should be considered as subject to many risks and uncertainties. For example, most drug candidates do not become approved drugs. Sirna currently does not have any clinical drug candidates for the treatment of respiratory diseases, and the development of Sirna-027 and Sirna-034 as well as Sirna's other programs are still at a relatively early stage. All of these programs, and Sirna's ability to obtain milestone and royalty payments for them, are subject to significant risks and unknowns, are highly contingent upon future successes, and require significant funding. In addition, patent applications may not result in issued patents, and issued patents may not be enforceable or could be invalidated. Other risks and uncertainties include, among others, Sirna's early stage of development and short operating history, Sirna's history and expectation of losses and need to raise capital, Sirna's need to obtain clinical validation and regulatory approval for Sirna-027, Sirna-034 and Sirna's other product candidates, any of which could have negative results, Sirna's need to engage collaborators, Sirna's need to obtain and protect intellectual property, and the risk of third-party patent infringement claims. These and additional risk factors are identified in Sirna's Securities and Exchange Commission filings, including Forms 10-K and 10-Q and in other SEC filings. Sirna undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release. Contacts: Greg Weaver SVP and Chief Financial Officer Sirna Therapeutics, Inc. 415-512-7200 Brandon Belcher The Ruth Group (646) 536-7009; DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Greg Weaver, SVP and Chief Financial Officer of Sirna Therapeutics, Inc., +1-415-512-7200; or Brandon Belcher of The Ruth Group, +1-646-536-7009, , for Sirna Therapeutics, Inc. Web site: http://www.unterberg.com/ Web site: http://www.sirna.com/

Copyright